ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
45 announcements
Four Indoco Remedies promoters bought 20,740 shares on NSE on 5 November 2026. Aggregate purchase value is about Rs.0.45 Crore.
Indoco Remedies promoter and director Suresh G Kare bought 1,335 equity shares on the open market on 6 November 2026, raising holding from 1.42% to 1.42%. The trade value is Rs.2,84,248, about Rs.0.03 Crore.
Indoco Remedies promoters Aditi M. Panandikar and Madhura Suresh Kare acquired a combined 5,996 equity shares via market purchase. The total transaction value is ₹0.13 Crore.
Indoco Remedies' promoters Aditi Panandikar and Madhura Suresh Kare acquired 8,004 shares via market purchase. The total transaction value is ₹0.17 Crore.
Indoco Remedies hit record quarterly revenue exceeding ₹500 Cr, but faced margin compression from elevated geopolitical freight and material costs.
Indoco's CRO AnaCipher received ANVISA Brazil approval for clinical and bioanalytical facilities. This expands its regulatory footprint to conduct bioequivalence studies in Brazil and Latin America.
Indoco Remedies Ltd reported revenue from operations of ₹506.9 Cr (+7.4% YoY) and net profit of ₹19.5 Cr for Q2 FY27.
Indoco Remedies allotted 14,850 ESOP shares to its Employees Welfare Trust under the 2022 ESOP plan. The allotment is at face value with no transaction price.
Indoco Remedies Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, in accordance with SEBI Regulation 31(1)(b).
Indoco Remedies intimated a board meeting on 27 Oct 2026 to approve Q1 FY27 standalone and consolidated results. Trading window remains closed until 29 Oct 2026.
Indoco Remedies Limited is incorporating a new wholly owned subsidiary, Warren Lifesciences Private Limited, for a cash investment of ₹0.01 Crore.
Indoco Remedies Limited has incorporated a new wholly-owned subsidiary, Warren Lifesciences Private Limited, to manufacture and develop pharmaceutical products.
Indoco Remedies disclosed an unsolicited Crisil ESG rating of 'Crisil ESG 60'. The company notes it did not engage Crisil for the assessment.
Indoco Remedies will incorporate a new wholly owned subsidiary, Warren Lifesciences Private Limited, for the pharmaceutical business with an initial capital of Rs. 1 Lakh.
Indoco Remedies filed proceedings of its 79th AGM held on 17 September 2026. Shareholders voted on nine resolutions including dividend and borrowing limits.
Indoco Remedies promoter Aditi M. Panandikar and PAC bought 38,930 shares on the open market, raising aggregate holding to 7.30%. No transaction price is disclosed in the filing.
Promoters Aditi M. Panandikar, Madhura Suresh Kare, Suresh G. Kare, and Aruna Suresh Kare acquired Indoco Remedies Ltd shares via market purchases, totaling ₹0.92 Crore.
Indoco Remedies received seven USFDA observations in Form 483 for its Plant II (Sterile) facility in Goa following an inspection from August 27 to September 4, 2026.
Promoters Aditi M. Panandikar and Madhura Suresh Kare each purchased 2,000 shares of Indoco Remedies from the open market. This reflects an increased promoter stake.
Promoters Aditi M. Panandikar and Madhura Suresh Kare acquired 10,000 equity shares of Indoco Remedies Limited. This open-market purchase increases the promoter group stake from 5.85% to 5.86%.
Promoters Aditi M. Panandikar and Madhura Suresh Kare acquired a total of 10,000 equity shares of Indoco Remedies Ltd through market purchases.
Indoco Remedies Limited has executed a Deed of Conveyance to sell a plot of land located at Mahal Industrial Estate to Kalpataru Townships Private Limited.
Indoco Remedies has executed a deed of conveyance to sell a land plot in Mumbai for a total consideration of ₹64 Crore.
Indoco Remedies has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-2026. The report provides disclosures on ESG, operations, and governance.
Indoco Remedies Limited has scheduled its 79th Annual General Meeting for September 17, 2026. The company also released its comprehensive Annual Report for the 2025-26 financial year.
Indoco Remedies Limited fixed September 10, 2026, as the record date for a final dividend of Rs. 0.20 per share. The 79th AGM is scheduled for September 17, 2026.
Indoco Remedies reported Q1FY27 consolidated revenue of INR 4,662 million, up 8.2% YoY. Management focuses on debt reduction, operational efficiency, and scaling domestic mid-sized brands while awaiting USFDA audits.
Indoco Remedies Limited re-appointed Ms. Aditi Panandikar as Managing Director for a five-year term. Mr. Sudhir Kadam was also appointed as Senior Management Personnel.
Indoco Remedies Ltd reported revenue from operations of ₹466.2 Cr (+8.2% YoY) and net profit of ₹65.4 Cr for Q1 FY27.
Indoco Remedies will hold a board meeting on July 28, 2026. The board will consider unaudited standalone and consolidated financial results for June quarter.